Stepan (NYSE:SCL) VP Sells $195,169.56 in Stock
Stepan (NYSE:SCL) VP Scott R. Behrens sold 2,004 shares of the business’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $97.39, for a total transaction of $195,169.56. Following the completion of the transaction, the vice president now directly owns 13,825 shares in the company, valued at $1,346,416.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Stepan stock traded down $2.34 during midday trading on Monday, reaching $97.03. The stock had a trading volume of 86,972 shares, compared to its average volume of 87,062. Stepan has a 12 month low of $69.17 and a 12 month high of $99.62. The business has a 50-day moving average of $91.80. The firm has a market cap of $2.25 billion, a price-to-earnings ratio of 19.89 and a beta of 1.30. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.69 and a quick ratio of 2.01.
Stepan (NYSE:SCL) last announced its quarterly earnings data on Wednesday, July 24th. The basic materials company reported $1.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.19. Stepan had a return on equity of 14.19% and a net margin of 5.39%. The business had revenue of $473.00 million for the quarter, compared to analysts’ expectations of $519.20 million. During the same period in the previous year, the business posted $1.38 EPS. The firm’s quarterly revenue was down 9.0% compared to the same quarter last year. On average, equities research analysts anticipate that Stepan will post 4.98 earnings per share for the current fiscal year.
A number of brokerages recently weighed in on SCL. ValuEngine downgraded shares of Whiting USA Trust II from a “hold” rating to a “sell” rating in a report on Tuesday, May 7th. Royal Bank of Canada set a $184.00 price target on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, July 3rd. Finally, Zacks Investment Research downgraded shares of Eisai from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 24th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $67.80.
A number of institutional investors have recently made changes to their positions in SCL. Arizona State Retirement System raised its holdings in Stepan by 1.0% in the second quarter. Arizona State Retirement System now owns 31,571 shares of the basic materials company’s stock worth $2,902,000 after purchasing an additional 310 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in Stepan by 9.5% in the second quarter. Nisa Investment Advisors LLC now owns 11,525 shares of the basic materials company’s stock worth $1,059,000 after purchasing an additional 1,000 shares in the last quarter. Hennessy Advisors Inc. bought a new position in Stepan in the second quarter worth $2,987,000. Contravisory Investment Management Inc. bought a new position in Stepan in the second quarter worth $151,000. Finally, WINTON GROUP Ltd raised its holdings in Stepan by 9.7% in the second quarter. WINTON GROUP Ltd now owns 9,543 shares of the basic materials company’s stock worth $877,000 after purchasing an additional 844 shares in the last quarter. Institutional investors and hedge funds own 71.95% of the company’s stock.
Stepan Company Profile
Stepan Company, together with its subsidiaries, produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products in North America, Europe, Latin America, and Asia. The company operates through three segments: Surfactants, Polymers, and Specialty Products.
Read More: Correction
Receive News & Ratings for Stepan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stepan and related companies with MarketBeat.com's FREE daily email newsletter.